Vaccination News Home Page                                            subscribe Vaccination NewsLetter

http://bmj.com/cgi/content/full/326/7396/952/c

Email this article to a friend Respond to this article PubMed citation Related articles in PubMed Download to Citation Manager Search Medline for articles by: Kumar, S. Alert me when: New articles cite this article

Collections under which this article appears: HIV Infection/AIDS

BMJ 2003;326:952 ( 3 May )
 

News extra

Trials of AIDS vaccine to start in India

New Delhi Sanjay Kumar

India is getting ready for the first trials of an AIDS vaccine. Phase I trials will begin later this year or early next year at the National AIDS Research Institute in Pune, Maharashtra.

The International AIDS Vaccine Initiative has been working closely with the Indian Council of Medical Research and the National AIDS Control Organisation since December 2000 to develop and evaluate AIDS vaccines in India.

To reduce fears that Indians will be used as guinea pigs for the trial of an AIDS vaccine that will be used only in the Western world, the initiative has been trying to forge collaborations with the government, non-governmental organisations, and policy makers at national and state levels.

A vaccine is projected as the last hope for the control of AIDS in India, which has some four million people who are HIV positive, the second largest concentration in one country after South Africa.

The first candidate vaccine to be tested in India will be modified vaccinia Ankara, a live attenuated vaccine that will target HIV-1 subtype C. "This subtype is predominant in India, accounting for nearly 91% of cases," said Dr Jean-Louis Excler, medical director of the initiative in India.

The other subtypes found mostly in northeastern India, albeit in smaller numbers, include subtypes A, B, and E and a recombinant subtype AC, he added. "There is, however, no really good epidemiological study of distribution of the various HIV subtypes in India," cautioned Dr Excler.

The vaccine is currently being developed by Therion Biologics, a company based in Boston, Massachusetts. Talks are taking place with some Indian companies for the manufacture of the vaccine in India when the phase I trials end, said Ms Anjali Nayyar, the International AIDS Vaccine Initiative’s country director for India. "We have at least two other candidate vaccines also in mind for testing in India, but a decision on that will be taken after later consultation with scientists," she said.

"Toxicology data will be submitted to the drugs controller of India by October this year, and we hope to get his permission for clinical trials soon thereafter," said Ms Nayyar.

In the first phase of clinical trials, which will last about a year, the vaccine will be tested on 39 HIV negative people at low risk of infection from the Pune area in western India. "We will ensure that informed consent is followed strictly and the trials are cleared by the institutional ethics committee," she added. The issue of monetary incentives could be looked into more seriously after the phase I trials are over, added Ms Nayyar.

"The vaccine is very safe," she assured, "and there is no possibility of volunteers getting infected through the vaccine." However, there could be minor side effects, which could be treated routinely, she added.
 


 

Email this article to a friend Respond to this article PubMed citation Related articles in PubMed Download to Citation Manager Search Medline for articles by: Kumar, S. Alert me when: New articles cite this article

Collections under which this article appears: HIV Infection/AIDS

© 2003 BMJ Publishing Group Ltd

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.